Results 251 to 260 of about 146,010 (350)
The effect of psilocin on neurotransmitters release in the claustrum and on rat behavior. [PDF]
Kościuk Z +3 more
europepmc +1 more source
Abstract INTRODUCTION Alzheimer's disease (AD) has been regarded as a brain‐first disorder. Emerging evidence suggests that the gut may influence central nervous system pathology, but the mechanisms remain unclear. METHODS We conducted a proteomic and microbial analysis of transverse colon samples from clinically and pathologically confirmed AD and ...
Qiwen Cheng +6 more
wiley +1 more source
Neuroimmune interactions in inflammatory bowel disease: Role of intestinal macrophages and the cholinergic pathway. [PDF]
Zheng L, Duan SL.
europepmc +1 more source
Abstract INTRODUCTION Adults with Down syndrome (DS) display increased Alzheimer's disease (AD) risk. The cholinergic system declines early in the AD continuum and relates to cognitive and functional decline. We aimed to identify the timeline of cholinergic decline in relation to hippocampal atrophy within the AT(N) framework in DS.
Jason K. Russell +7 more
wiley +1 more source
Cholinergic system in patients with chronic kidney disease: cognitive and renal implications. [PDF]
Xu H +13 more
europepmc +1 more source
Heartfelt intervention: A role for PVN oxytocin neurons in the prediabetic heart
The Journal of Physiology, EarlyView.
Grace K. Nielsen +2 more
wiley +1 more source
Abstract INTRODUCTION With the approval of lecanemab for treating Alzheimer's disease (AD), there is an urgent need to evaluate its safety and treatment effects on biomarkers in real‐world practice. METHODS Patients receiving lecanemab (n = 72) underwent routine 3T and 7T magnetic resonance imaging (MRI) for amyloid‐related imaging abnormality (ARIA ...
Weiwei Zhang +12 more
wiley +1 more source

